Patents Examined by Iqbal H Chowdhury
  • Patent number: 11634456
    Abstract: A process for the extraction of collagen from collagen-containing matter, wherein the process comprises; incubating the collagen-containing matter in an acidic solution to form an incubant, then diafiltrating the incubant to substantially purify solubilised collagen within the incubant, thereby forming a retentate, then separating the soluble and insoluble matter of the retentate to remove the remaining insoluble matter, wherein the soluble matter is a substantially pure collagen solution.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: April 25, 2023
    Assignee: JELLAGEN PTY LTD
    Inventor: Andrew Mearns Spragg
  • Patent number: 11634735
    Abstract: The present invention provides for novel metabolic pathways leading to propanol, alcohol or polyol formation in a consolidated bioprocessing system (CBP), where lignocellulosic biomass is efficiently converted to such products. More specifically, the invention provides for a recombinant microorganism, where the microorganism expresses one or more native and/or heterologous enzymes; where the one or more enzymes function in one or more engineered metabolic pathways to achieve: (1) conversion of a carbohydrate source to 1,2-propanediol, isopropropanol, ethanol and/or glycerol; (2) conversion of a carbohydrate source to n-propanol and isopropanol; (3) conversion of a carbohydrate source to isopropanol and methanol; or (4) conversion of a carbohydrate source to propanediol and acetone; wherein the one or more native and/or heterologous enzymes is activated, upregulated or downregulated.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: April 25, 2023
    Assignee: Lallemand Hungary Liquidity Management LLC
    Inventors: John E. McBride, Vineet Rajgarhia, Arthur J. Shaw, IV, Shital A. Tripathi, Elena Brevnova, Nicky Caiazza, Johannes Pieter Van Dijken, Allan C. Froehlich, William Ryan Sillers, James H. Flatt
  • Patent number: 11634720
    Abstract: The technical field of preparation of organic compounds, and particularly to yeasts producing tyrosol or hydroxytyrosol and construction methods thereof. PcAAS and ADH-encoding DNA sequences are introduced into the yeast strain BY4741, to obtain a PcAAS-ADH recombinant yeast producing tyrosol. A PDC1 knockout cassette and a TyrA expression cassette are introduced into the PcAAS-ADH recombinant yeast to obtain a PcAAS-ADH-?PDC1-TyrA recombinant yeast producing tyrosol. A HpaBC encoding DNA sequence is introduced into the PcAAS-ADH-?PDC1-TyrA recombinant yeast, to obtain a PcAAS-ADH-HpaBC-?PDC1-TyrA recombinant yeast producing hydroxytyrosol. The construction of a tyrosol or hydroxytyrosol biosynthesis pathway in the yeast strain BY4741 enhances the production of tyrosol or hydroxytyrosol.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: April 25, 2023
    Assignee: SHANDONG HENGLU BIOTECH. CO., LTD.
    Inventors: Xu Fang, Wei Guo, Lijuan Han
  • Patent number: 11629372
    Abstract: Compositions comprise statistically random heteropolymers complexed with active proteins, and are formulated and used in stimuli-responsive materials and nanoreactors composed of proteins and synthetic materials.
    Type: Grant
    Filed: June 21, 2020
    Date of Patent: April 18, 2023
    Assignee: The Regents of the University of California
    Inventors: Ting Xu, Brian Panganiban, Tao Jiang
  • Patent number: 11613745
    Abstract: The present invention relates to a recombinant OxDC expressed in a filamentous fungal host cell, methods for constructing a recombinant filamentous fungal host cell, methods for producing recombinant OxDC and the application thereof. The recombinant filamentous fungal host cell comprises one or more copies of OxDC expression cassette integrated in its genome; the expression cassette comprises a promoter, a signal peptide coding sequence, an OxDC coding sequence and a transcription terminator. The host cell can be constructed by random integration or site-specific integration. In addition, the present invention also optimizes the medium formulation for different recombinant filamentous fungal host cells. In the production of the recombinant OxDC, the final yield and enzyme activity were greatly improved. The invention effectively solves the problem that the production of OxDC in the prior art cannot be industrialized on a large scale.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: March 28, 2023
    Assignee: WUHAN KANGFUDE BIOTECHNOLOGY CO., LTD.
    Inventors: Wei Wang, Xiaofeng Wang, Yanhong Liu, He Huang, Huoqing Chen, Xianqiao Chen
  • Patent number: 11603549
    Abstract: Described herein are devices and methods for using the same to produce carotenoids. The carotenoids produced by the devices and methods disclosed herein do not require the ultra purification that is common in conventional or commercial methods. The devices and methods disclosed herein also enhance one or more physical properties of plants treated with the devices described herein.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: March 14, 2023
    Assignee: Bio Capital Holdings, LLC
    Inventor: Raul Cuero Rengifo
  • Patent number: 11597954
    Abstract: This invention relates to the bioproduction of substituted or unsubstituted phenylacetaldehyde, 2-phenylethanol, phenylacetic acid or phenylethylamine by subjecting a starting material comprising glucose, L-phenylalanine, substituted L-phenylalanine, styrene or substituted styrene to a plurality of enzyme catalyzed chemical transformations in a one-pot reaction system, using recombinant microbial cells overexpressing the enzymes. To produce phenylacetaldehyde from styrene, the cells are modified to overexpress styrene monooxygenase (SMO) and styrene oxide isomerase (SOI). To produce phenylacetic acid from styrene, SMO, SOI and aldehyde dehydrogenase are overexpressed. Alternatively, to produce 2-phenylethanol, SMO, SOI and aldehyde reductase or alcohol dehydrogenase are overexpressed, while to produce phenylethylamine, SMO, SOI and transaminase are overexpressed.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: March 7, 2023
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Zhi Li, Shuke Wu, Yi Zhou, Benedict Ryan Lukito
  • Patent number: 11591626
    Abstract: A DNA expression construct comprising a polynucleotide encoding an unnatural UstD enzyme, the unnatural enzyme itself, and a method of making gamma-hydroxy amino acids by contacting an aldehyde-containing substrate, an amino acid, and the unnatural, purified UstD enzyme under conditions and for a time sufficient to react at least a portion of the aldehyde-containing substrate with at least a portion of the amino acid, to yield a gamma-hydroxy amino acid product.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: February 28, 2023
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Andrew R. Buller, Jonathan M. Ellis, Prasanth Kumar
  • Patent number: 11591376
    Abstract: The present invention provides an isolated AZF1 gene sequence, recombinant vectors, and recombinant yeast which are useful in methods of enhanced biofuel production, particularly ethanol production. Methods of bioengineering recombinant yeast with isolated AZF1 gene sequence useful for biofuel production are also provided.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: February 28, 2023
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Audrey P. Gasch, Kevin Myers
  • Patent number: 11572549
    Abstract: The present invention provides several non-naturally occurring sulfotransferase enzymes that have been engineered to react with aryl sulfate compounds as sulfo group donors, instead of the natural substrate 3?-phosphoadenosine 5?-phosphosulfate (PAPS), and with heparosan-based polysaccharides, particularly heparan sulfate, as sulfo group acceptors. Each of the engineered sulfotransferase enzymes have a biological activity characterized by the position within the heparosan-based polysaccharide that receives the sulfo group, including glucosaminyl N-sulfotransferase activity, hexuronyl 2-O sulfotransferase activity, glucosaminyl 6-O sulfotransferase activity, or glucosaminyl 3-O sulfotransferase activity. Methods of using the engineered sulfotransferases to produce sulfated heparosan-based polysaccharides, including polysaccharides having anticoagulant activity, are also provided.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: February 7, 2023
    Assignee: OPTIMVIA, LLC
    Inventor: Tarsis Gesteira Ferreira
  • Patent number: 11572550
    Abstract: The present invention provides several non-naturally occurring sulfotransferase enzymes that have been engineered to react with aryl sulfate compounds as sulfo group donors, instead of the natural substrate 3?-phosphoadenosine 5?-phosphosulfate (PAPS), and with heparosan-based polysaccharides, particularly heparan sulfate, as sulfo group acceptors. Each of the engineered sulfotransferase enzymes have a biological activity characterized by the position within the heparosan-based polysaccharide that receives the sulfo group, including glucosaminyl N-sulfotransferase activity, hexuronyl 2-O sulfotransferase activity, glucosaminyl 6-O sulfotransferase activity, or glucosaminyl 3-O sulfotransferase activity. Methods of using the engineered sulfotransferases to produce sulfated heparosan-based polysaccharides, including polysaccharides having anticoagulant activity, are also provided.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: February 7, 2023
    Assignee: OPTIMVIA, LLC
    Inventor: Tarsis Gesteira Ferreira
  • Patent number: 11566249
    Abstract: A DNA fragment to encode a nitrogen fixation enzyme includes a base sequence of SEQ ID NO:1 or a base sequence having not less than 50% identity with the SEQ ID NO:1.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: January 31, 2023
    Assignee: TOYOTA BOSHOKU KABUSHIKI KAISHA
    Inventor: Masaro Akai
  • Patent number: 11566204
    Abstract: According to the present disclosure, on the basis of all existing mutations, the tenth glycine of a BC-PC-PLC is mutated into aspartic acid, a specific enzyme activity thereof is 83% higher than that of a sequence before the mutation, and protein expression and degumming activity of unit enzyme activity do not change, so as to further reduce manufacturing costs.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: January 31, 2023
    Assignee: Wilmar (Shanghai) Biotechnology Research & Development Center Co., Ltd.
    Inventors: Wei Wu, Xiaojun Dai, Haisheng Cao, Qiwen Niu
  • Patent number: 11564978
    Abstract: Disclosed herein are methods for treating a subject with an alkaline phosphatase deficiency, further comprising monitoring additional analytes, e.g., calcium, parathyroid hormone and/or vitamin D, with treatment modifications as indicated by the levels, e.g., serum levels, of the additional analytes.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: January 31, 2023
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventor: Tatjana Odrljin
  • Patent number: 11566239
    Abstract: Disclosed is variants of a cellulase having improved stability in the presence of a protease, and the use of such variants in laundry.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: January 31, 2023
    Assignee: Novozymes A/S
    Inventors: Svend Gunnar Kaasgaard, Frank Winther Rasmussen, Roland Alexander Pache, Lars Anderson, Mette Louise Dissing Overgaard, Thomas Agersten Poulsen, Dorte Marie Koefoed Klitgaard, Christian Isak Joergensen, Lars Giger
  • Patent number: 11549950
    Abstract: Disclosed herein is a rapid genetics-free method for eliciting and detecting cryptic metabolites using an imaging mass spectrometry-based approach. An organism of choice is challenged with elicitors from a small molecule library. The molecules elicited are then imaged by mass spec, which allows for rapid identification of cryptic metabolites. These are then isolated and characterized. Employing the disclosed approach activated production of cryptic glycopeptides from an actinomycete bacterium. The molecules that result, the keratinimicins and keratinicyclins, are metabolites with important structural features. At least two of these, keratinimicins B and C, are highly bioactive against several pathogenic strains. This approach will allow for rapid activation and identification of cryptic metabolites from diverse microorganisms in the future.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: January 10, 2023
    Inventors: Mohammad R. Seyedsayamdost, Fei Xu, Yihan Wu, Leah Bushin, Katherine Davis
  • Patent number: 11549115
    Abstract: The present invention provides compositions and methods for regulated gene expression. In certain aspects, the invention relates to an inducible synthetic promoter that can be used for regulated gene expression or to generate mutations in one or more bacterial cells of the gut microbiota.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: January 10, 2023
    Assignee: Yale University
    Inventors: Andrew Goodman, Bentley Lim, Natasha Barry
  • Patent number: 11549116
    Abstract: A nucleic acid molecule comprising a variant inc coding strand is disclosed as a regulator of plasmid copy number. Also disclosed is a replicon comprising the nucleic acid molecule, a promoter, and an origin of replication. Also disclosed is a vector comprising the replicon. Also disclosed is a recombinant microorganism comprising the vector.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: January 10, 2023
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Ji Sun Lee, Dong Eun Chang, Sang Jun Kim, So Young Kim
  • Patent number: 11542537
    Abstract: Methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and M are described. The methods include utilizing recombinant microorganisms for converting various staring compositions to target steviol glycosides. In addition, novel steviol glycosides reb D2 and reb M2 are disclosed, as are methods of preparing the same. The highly purified rebaudiosides are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: January 3, 2023
    Assignee: PURECIRCLE SDN BHD
    Inventors: Avetik Markosyan, Indra Prakash, Cynthia Bunders, Pankaj Soni, Jarrin Cyrille, Aurélien Badie, Robert ter Halle
  • Patent number: 11542491
    Abstract: A fusion tag according to an embodiment of the present invention may increase the water solubility and expression level of a target protein. As the water solubility and expression level of a target protein in host cell can be increased by a recombinant vector including the fusion tag, the fusion tag can be advantageously used in industry.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: January 3, 2023
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventor: Byung-hoon Jo